Market research
EYEG AB Corporate Bond ETF
NASDAQ USD
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- Not available
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.8
Community
Investor discussion
1 comment
Sign in to join the EYEG discussion.
5 years, 4 months ago
EyeGate Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 25.8% below its 200 day moving average.
From a valuation standpoint, the stock is 41.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1893.6.
EyeGate Pharmaceuticals, Inc's total revenue rose by inf% to $12K since the same quarter in the previous year.
Its net income has increased by 100.0% to $0 since the same quarter in the previous year.
Finally, its free cash flow grew by 33.1% to $-2M since the same quarter in the previous year.
Based on the above factors, EyeGate Pharmaceuticals, Inc gets an overall score of 3/5.